In a battle with Bristol Myers Squibb/Johnson & Johnson, Bayer and privately held Anthos to bring the first factor XI anticoagulant product to market, Regeneron reported on 19 December that its pair of factor XI-targeted antibodies succeeded in Phase II studies and are expected to advance into Phase III in 2025.
Key Takeaways
- Regeneron plans to advance its two factor XI anticoagulant candidates into Phase III after reporting positive data from two Phase II trials.
The Tarrytown, NY-based firm is developing REGN7508, which targets factor XI’s catalytic domain, and REGN9933, which acts on the A2...